Alpine Immune Sciences (ALPN) News Today → Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad) Free ALPN Stock Alerts $64.97 +0.01 (+0.02%) (As of 05/17/2024) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 10 at 1:20 AM | americanbankingnews.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Average Rating of "Hold" from BrokeragesMay 25, 2024 | marketbeat.comBNP Paribas Financial Markets Buys 93,423 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)BNP Paribas Financial Markets grew its position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 691.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 106,941 shares of the biotechnology company's stock after buying aMay 20, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Reaches New 12-Month High at $65.00Alpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $65.00May 18, 2024 | marketbeat.comJump Financial LLC Buys Shares of 55,720 Alpine Immune Sciences, Inc. (NASDAQ:ALPN)Jump Financial LLC bought a new position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 55,720 shares of the biotechnology company's stock, valued at approximately $1,062,00May 16, 2024 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About Alpine Immune SciencesMay 16, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Given "Neutral" Rating at WedbushWedbush reissued a "neutral" rating and set a $65.00 price objective on shares of Alpine Immune Sciences in a report on Thursday.May 16, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Recommendation of "Hold" from AnalystsShares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) have received a consensus rating of "Hold" from the eleven analysts that are covering the stock, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a hold recommendation and three have assigned a buMay 14, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Reaches New 52-Week High at $64.96Alpine Immune Sciences (NASDAQ:ALPN) Hits New 12-Month High at $64.96May 13, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Significant Drop in Short InterestAlpine Immune Sciences, Inc. (NASDAQ:ALPN - Get Free Report) saw a significant decline in short interest in April. As of April 30th, there was short interest totalling 3,890,000 shares, a decline of 17.9% from the April 15th total of 4,740,000 shares. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is currently 1.7 days.May 10, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume IncreaseAlpine Immune Sciences (NASDAQ:ALPN) Sees Large Volume IncreaseMay 10, 2024 | investorplace.comALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024May 9, 2024 | businesswire.comAlpine Immune Sciences Reports First Quarter 2024 Financial ResultsMay 9, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Sold by Vivo Capital LLCVivo Capital LLC lowered its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 10.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 819,275 shares of the biotechnology company's stock afterMay 8, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sets New 52-Week High at $64.72Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.72May 7, 2024 | finance.yahoo.comVertex Pharmaceuticals Inc (VRTX) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...May 1, 2024 | morningstar.comAlpine Immune Sciences IncApril 29, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.70Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.70April 27, 2024 | marketbeat.comVivo Capital LLC Sells 298,770 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN)Vivo Capital LLC lessened its stake in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 36.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 520,505 shares of the biotechnology company's stock after selling 298,770 shares duriApril 27, 2024 | benzinga.comLatest News for Alpine Immune Sciences Stock (NASDAQ:ALPN)April 27, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune ...April 26, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 23, 2024 | finance.yahoo.comAlpine Immune Sciences, Inc. (ALPN)April 22, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Sets New 1-Year High at $64.58Alpine Immune Sciences (NASDAQ:ALPN) Sets New 12-Month High at $64.58April 18, 2024 | msn.comTD Cowen Downgrades Alpine Immune Sciences (ALPN)April 17, 2024 | prnewswire.comINVESTIGATION: The M&A Class Action Firm Announces an Investigation of Alpine Immune Sciences, Inc. - ALPNApril 17, 2024 | msn.comAlpine Immune Sciences (ALPN) Price Target Increased by 36.91% to 63.24April 16, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Given "Hold" Rating at TD CowenTD Cowen reaffirmed a "hold" rating on shares of Alpine Immune Sciences in a research note on Tuesday.April 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 15, 2024 | marketbeat.comAlpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Bought by Vanguard Group Inc.Vanguard Group Inc. increased its holdings in Alpine Immune Sciences, Inc. (NASDAQ:ALPN - Free Report) by 5.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,474,879 shares of the biotechnology company's stock afterApril 13, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Downgraded by Leerink Partnrs to Market PerformLeerink Partnrs cut Alpine Immune Sciences from an "outperform" rating to a "market perform" rating in a report on Thursday.April 13, 2024 | fool.comCould This Stock Be the Next Biotech Buyout?April 12, 2024 | stockhouse.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Alpine Immune Sciences, Inc. BuyoutApril 12, 2024 | businesswire.comALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPNApril 12, 2024 | marketbeat.comAlpine Immune Sciences' (ALPN) "Market Perform" Rating Reaffirmed at SVB LeerinkSVB Leerink reissued a "market perform" rating and set a $65.00 price target (up previously from $42.00) on shares of Alpine Immune Sciences in a research report on Friday.April 12, 2024 | marketbeat.comAlpine Immune Sciences (NASDAQ:ALPN) Downgraded by HC WainwrightHC Wainwright downgraded Alpine Immune Sciences from a "buy" rating to a "neutral" rating in a report on Thursday.April 11, 2024 | finance.yahoo.comThese Stocks Moved the Most Today: CarMax, Apple, Fastenal, Rivian, Alpine Immune, Nike, Robinhood, Constellation Brands, and MoreApril 11, 2024 | seekingalpha.comVertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'April 11, 2024 | barrons.comVertex Pharmaceuticals to Buy Alpine Immune in $4.9B DealApril 11, 2024 | investors.comAlpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy ItApril 11, 2024 | investorplace.comThe $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% TodayApril 11, 2024 | marketbeat.comAlpine Immune Sciences' (ALPN) "Neutral" Rating Reaffirmed at WedbushWedbush reaffirmed a "neutral" rating on shares of Alpine Immune Sciences in a research report on Thursday.April 11, 2024 | proactiveinvestors.comAlpine Immune Sciences soars on $4.9bn Vertex takeoverApril 10, 2024 | investopedia.comVertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to WatchApril 10, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Alpine Immune Sciences, Inc. has obtained a Fair Price in its transaction with VertexApril 10, 2024 | businesswire.comALPN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alpine Immune Sciences, Inc. Is Fair to ShareholdersApril 10, 2024 | investors.comVertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion DealApril 10, 2024 | reuters.comVertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 blnApril 10, 2024 | marketbeat.comTrading was temporarily halted for "ALPN" at 04:04 PM with a stated reason of "News pending."April 10, 2024 | bloomberg.comAlpine Immune Is Weighing Options After Takeover InterestApril 10, 2024 | benzinga.comWhy Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday? Get Alpine Immune Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Email Address No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (Ad)Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight! TRY "INVESTING IDEAS" TODAY ALPN Media Mentions By Week ALPN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALPN News Sentiment▼0.000.76▲Average Medical News Sentiment ALPN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALPN Articles This Week▼13▲ALPN Articles Average Week Get Alpine Immune Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ALPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XNCR News ZYME News HARP News MGNX News ASMB News RPRX News BMRN News BGNE News VTRS News UTHR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALPN) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored